Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways. Suzuki Y, Usuki S, Nishizawa M, Tanaka N, et al. Anticancer Res 2025;45:2265-2278.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Suzuki Y, Usuki S, Nishizawa M, Tanaka N, et al. Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways. Anticancer Res 2025;45:2265-2278.
PMID: 40425334